News
Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback